Relationship between uric acid and prognosis of Chinese patients with acute ischemic stroke: A meta analysis

doi:10.3969/j.issn.1004-583X.2022.09.003

Abstract

Abstract:

Objective The meta analysis method was applied to comprehensively and systematically evaluate relations between uric acid and prognosis of Chinese patients with acute ischemic stroke.Methods PubMed, Web of Science, Embase, Cochrane Library, CNKI, VIP and Wanfang databases were searched by computer system to collect case-control studies on relation between the level of uric acid and prognosis of patients with acute ischemic stroke in Chinese from database establishment to February 2022. The Meta analysis was performed using STATA 16 software. Results Thirteen literatures representing a total of 11, 046 study subjects (n=8, 016 in the good prognosis group, and n=3 030 in the poor prognosis group) were included in the meta-analysis. The results showed that the uric acid level of patients in the good prognosis group was higher than that of poor prognosis group [WMD=18.44 μmol/L, 95%CI(3.20, 33.68), P<0.05]. The results of sensitivity analysis and publication bias test showed that the study results were stable and reliable.Conclusion The level of uric acid in Chinese may be related to the prognosis of patients with acute ischemic stroke, and the higher level of uric acid in Chinese patients may have a better prognosis.

Key words: uric acid, acute ischemic stroke, prognosis, China, Meta-analysis

CLC Number:

R743.33

Wang Huixin, Zhao Fangqing, Zhang Xinyan, Hou Xiaowen. Relationship between uric acid and prognosis of Chinese patients with acute ischemic stroke: A meta analysis[J]. Clinical Focus, 2022, 37(9): 785-790.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2022.09.003

https://huicui.hebmu.edu.cn/EN/Y2022/V37/I9/785

Figures/Tables 5

References 37

[1]	Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics-2021 update: A report from the American Heart Association[J]. Circulation, 2021, 143(8): e254-e743. doi: 10.1161/CIR.0000000000000950 pmid: 33501848
[2]	Wu TC, Grotta JC. Hypothermia for acute ischemic stroke[J]. Lancet Neurol, 2013, 12(3): 275-284. doi: 10.1016/S1474-4422(13)70013-9 URL
[3]	Lipton P. Ischemic cell death in neurons[J]. Physiol Rev, 1999, 79(4): 1431-1568. doi: 10.1152/physrev.1999.79.4.1431 pmid: 10508238
[4]	Becker BF. Towards the physiological function of uric acid[J]. Free Radic Biol Med, 1993, 14(6): 615-631. doi: 10.1016/0891-5849(93)90143-I URL
[5]	Glantzounis GK, Tsimoyiannis EC, Kappas AM, et al. Uric acid and oxidative stress[J]. Curr Pharm Des, 2005, 11(32): 4145-4151. doi: 10.2174/138161205774913255 URL
[6]	中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志, 2018, 51(9): 666-682.
[7]	Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol, 2010, 25(9): 603-605. doi: 10.1007/s10654-010-9491-z pmid: 20652370
[8]	Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias[J]. Biometrics, 1994, 50(4): 1088-1101. pmid: 7786990
[9]	Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test[J]. BMJ, 1997, 315(7109): 629-634. doi: 10.1136/bmj.315.7109.629 pmid: 9310563
[10]	张毅, 郭升, 武春桃, 等. 血清尿酸水平对急性缺血性脑卒中早期预后的影响[J]. 中国实用神经疾病杂志, 2020, 23(22): 1967-1972.
[11]	郝美美, 陈晨, 袁兴运, 等. 尿酸与急性缺血性脑卒中早期预后关系的研究[J]. 中华老年心脑血管病杂志, 2019, 21(5): 515-518.
[12]	张静. 高尿酸与接受溶栓治疗的急性缺血性脑卒中患者长期预后独立相关[D]. 大连: 大连医科大学, 2019.
[13]	Zhang X, Huang ZC, Lu TS, et al. Prognostic significance of uric acid levels in ischemic stroke patients[J]. Neurotox Res, 2016, 29(1): 10-20. doi: 10.1007/s12640-015-9561-9 pmid: 26376636
[14]	林友榆, 胡治平, 黄银辉, 等. 血尿酸水平与重组组织型纤溶酶原激活剂静脉溶栓治疗急性缺血性脑卒中患者预后的关系[J]. 中华全科医师杂志, 2016, 15(3): 198-201.
[15]	李芳. 急性期脑梗死血尿酸水平与出院结局关系的研究[D]. 南充: 川北医学院, 2016.
[16]	Liu X, Liu M, Chen M, et al. Serum uric acid is neuroprotective in Chinese patients with acute ischemic stroke treated with intravenous recombinant tissue plasminogen activator[J]. J Stroke Cerebrovasc Dis, 2015, 24(5): 1080-1086. doi: 10.1016/j.jstrokecerebrovasdis.2015.01.011 pmid: 25817625
[17]	国钰梅, 马龙, 潘国涛, 等. 急性缺血性脑卒中患者同型半胱氨酸水平与出院结局的关联研究[J]. 现代检验医学杂志, 2016, 31(5): 23-26.
[18]	谷新医, 刘文博, 孙建平, 等. 尿酸水平与急性缺血性脑卒中出院不良结局的关系[J]. 中国实用神经疾病杂志, 2014, 17(23): 67-69.
[19]	血清尿酸水平对静脉溶栓治疗后急性缺血性脑卒中患者预后的影响[C]. 中国急救医学, 2013, 5(33): 420-423.
[20]	林绍鹏, 潘速跃. 血清尿酸浓度对急性缺血性卒中患者短期转归的影响: 回顾性病例系列研究[J]. 国际脑血管病杂志, 2013, 21(7): 527-530.
[21]	韩玉乐. 影响急性缺血性卒中早期预后的相关因素分析[D]. 广州: 广州医学院, 2013.
[22]	Zhang B, Gao C, Yang N, et al. Is elevated SUA associated with a worse outcome in young Chinese patients with acute cerebral ischemic stroke?[J]. BMC Neurol, 2010, 10: 82. doi: 10.1186/1471-2377-10-82 pmid: 20849639
[23]	Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range[J]. BMC Med Res Methodol, 2014, 14:135. doi: 10.1186/1471-2288-14-135 pmid: 25524443
[24]	Ames BN, Cathcart R, Schwiers E, et al. Uric acid provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer: A hypothesis[J]. Proc Natl Acad Sci USA, 1981, 78(11): 6858-6862. doi: 10.1073/pnas.78.11.6858 URL
[25]	Waring WS, Webb DJ, Maxwell SR. Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers[J]. Cardiovasc Pharmacol, 2001, 38(3):365-371. doi: 10.1097/00005344-200109000-00005 URL
[26]	Squadrito GL, Cueto R, Splenser AE, et al. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid[J]. Arch Biochem Biophys, 2000, 376(2): 333-337. pmid: 10775420
[27]	Kanellis J, Watanabe S, Li JH, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2[J]. Hypertension, 2003, 41(6): 1287-1293. pmid: 12743010
[28]	Kang DH, Han L, Ouyang X, et al. Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter[J]. Am J Nephrol, 2005, 25(5): 425-433. doi: 10.1159/000087713 URL
[29]	Santos CX, Anjos EI, Augusto O. Uric acid oxidation by peroxynitrite: multiple reactions, free radical formation, and amplification of lipid oxidation[J]. Arch Biochem Biophys, 1999, 372(2): 285-294. pmid: 10600166
[30]	Shao Y, Shao H, Sawhney MS, et al. Serum uric acid as a risk factor of all-cause mortality and cardiovascular events among type 2 diabetes population: meta-analysis of correlational evidence[J]. J Diabetes Complications, 2019, 33(10): 107409. doi: 10.1016/j.jdiacomp.2019.07.006 URL
[31]	Arora T, Mantur PG, Bidri RC, et al. Serum uric acid levels and serum lipid levels in patients with ischemic cerebrovascular accident[J]. J Assoc Physicians India, 2018, 66(7): 66-68. pmid: 31325266
[32]	Crosta F, Occhiuzzi U, Passalacqua G, et al. Association between the serum uric acid levels and lacunar infarcts in the elderly[J]. J Mol Neurosci, 2018, 65(3): 385-390. doi: 10.1007/s12031-018-1096-0 pmid: 29974380
[33]	Yu ZF, Bruce-Keller AJ, Goodman Y, et al. Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo[J]. J Neurosci Res, 1998, 53(5): 613-625. pmid: 9726432
[34]	Cutler RG, Camandola S, Feldman NH, et al. Uric acid enhances longevity and endurance and protects the brain against ischemia[J]. Neurobiol Aging, 2019, 75:159-168. doi: S0197-4580(18)30438-X pmid: 30576885
[35]	Tariq MA, Shamim SA, Rana KF, et al. Serum uric acid - risk factor for acute ischemic stroke and poor outcomes[J]. Cureus, 2019, 11(10):e6007.
[36]	Amaro S, Soy D, Obach V, et al. A pilot study of dual treatment with recombinant tissue plasminogen activator and uric acid in acute ischemic stroke[J]. Stroke, 2007, 38(7): 2173-2175. pmid: 17525395
[37]	Chamorro A, Amaro S, Castellanos M, et al. Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): A randomised, double-blind phase 2b/3 trial[J]. Lancet Neurol, 2014, 13(5): 453-460. doi: 10.1016/S1474-4422(14)70054-7 pmid: 24703208

第一作者	发表年份	平均年龄 (岁)	男性 (%)	样本量(例)		入院时尿酸 (μmol/L)		预后良好的定义标准
第一作者	发表年份	平均年龄 (岁)	男性 (%)	预后良好组	预后不良组	预后良好组	预后不良组	预后良好的定义标准
张毅^[10]	2020	60.2	66.5	125	78	227.1±19.4	268.6±50.2	出院时mRS≤2
郝美美^[11]	2019	62.4	61.8	232	189	322.0±87.4	281.3±86.2	出院时mRS≤2
张静^[12]	2019	63.2	71.2	236	167	343.9±102.7	311.2±110.7	90天mRS≤1
Zhang ^[13]	2016	64.6	66.3	196	107	319.9±93.9	317.6±83.6	90天mRS≤1
林友榆^[14]	2016	77.7	47.7	93	83	404.4±151.7	345.6±107.5	90天mRS≤1
李芳^[15]	2016	68.6	58.8	1 224	795	314.8±92.7	301.7±106.1	出院时mRS≤2
Liu^[16]	2015	63.9	63.4	112	104	331.5±103.4	277.7±105.6	90天mRS≤1
国钰梅^[17]	2016	62.3	39.5	3 081	359	301.8±93.6	295.5±100.9	出院时mRS≤2
谷新医^[18]	2014	69.5	81.6	1 965	566	321.8±94.8	313.8±100.8	出院时mRS≤2
刘宣^[19]	2013	64.1	61.9	46	38	341.1±112.1	272.1±88.0	90天mRS≤1
林绍鹏^[20]	2013	69.6	61.1	185	126	363.3±100.7	332.0±119.0	出院时mRS≤2
韩玉乐^[21]	2013	74.4	49.4	239	89	367.0±119.0	392.7±146.6	出院时mRS≤2
Zhang^[22]	2010	39.5	66.7	426	159	326.2±103.4	295.7±111.2	出院时mRS≤2

第一作者	发表年份	平均年龄 (岁)	男性 (%)	样本量(例)		入院时尿酸 (μmol/L)		预后良好的定义标准
第一作者	发表年份	平均年龄 (岁)	男性 (%)	预后良好组	预后不良组	预后良好组	预后不良组	预后良好的定义标准
张毅^[10]	2020	60.2	66.5	125	78	227.1±19.4	268.6±50.2	出院时mRS≤2
郝美美^[11]	2019	62.4	61.8	232	189	322.0±87.4	281.3±86.2	出院时mRS≤2
张静^[12]	2019	63.2	71.2	236	167	343.9±102.7	311.2±110.7	90天mRS≤1
Zhang ^[13]	2016	64.6	66.3	196	107	319.9±93.9	317.6±83.6	90天mRS≤1
林友榆^[14]	2016	77.7	47.7	93	83	404.4±151.7	345.6±107.5	90天mRS≤1
李芳^[15]	2016	68.6	58.8	1 224	795	314.8±92.7	301.7±106.1	出院时mRS≤2
Liu^[16]	2015	63.9	63.4	112	104	331.5±103.4	277.7±105.6	90天mRS≤1
国钰梅^[17]	2016	62.3	39.5	3 081	359	301.8±93.6	295.5±100.9	出院时mRS≤2
谷新医^[18]	2014	69.5	81.6	1 965	566	321.8±94.8	313.8±100.8	出院时mRS≤2
刘宣^[19]	2013	64.1	61.9	46	38	341.1±112.1	272.1±88.0	90天mRS≤1
林绍鹏^[20]	2013	69.6	61.1	185	126	363.3±100.7	332.0±119.0	出院时mRS≤2
韩玉乐^[21]	2013	74.4	49.4	239	89	367.0±119.0	392.7±146.6	出院时mRS≤2
Zhang^[22]	2010	39.5	66.7	426	159	326.2±103.4	295.7±111.2	出院时mRS≤2

第一作者	病例的定义和诊断是否恰当	病例是否具有代表性	对照组的选择方法	对照的描述是否充分	最重要的因素在两组中可比	其他重要的因素在两组中可比	暴露的确定方法	病例和对照的检测方法是否相同	两组无应答率相同	质量评分 (分)
张毅^[10]	√	√	√	×	×	×	√	√	√	6
郝美美^[11]	√	√	√	×	×	×	√	√	√	6
张静^[12]	√	√	√	√	×	×	√	√	√	7
Zhang^[13]	√	√	√	√	×	×	√	√	√	7
林友榆^[14]	√	√	√	√	√	×	√	√	√	8
李芳^[15]	√	√	√	√	√	×	√	√	√	8
Liu^[16]	√	√	√	×	×	×	√	√	√	6
国钰梅^[17]	√	√	√	×	√	×	√	√	√	7
谷新医^[18]	√	√	√	×	√	√	√	√	√	8
刘宣^[19]	√	√	√	√	×	×	√	√	√	7
林绍鹏^[20]	√	√	√	×	×	×	√	√	√	6
韩玉乐^[21]	√	√	√	×	×	×	√	√	√	6
Zhang^[22]	√	√	√	×	×	×	√	√	√	6

第一作者	病例的定义和诊断是否恰当	病例是否具有代表性	对照组的选择方法	对照的描述是否充分	最重要的因素在两组中可比	其他重要的因素在两组中可比	暴露的确定方法	病例和对照的检测方法是否相同	两组无应答率相同	质量评分 (分)
张毅^[10]	√	√	√	×	×	×	√	√	√	6
郝美美^[11]	√	√	√	×	×	×	√	√	√	6
张静^[12]	√	√	√	√	×	×	√	√	√	7
Zhang^[13]	√	√	√	√	×	×	√	√	√	7
林友榆^[14]	√	√	√	√	√	×	√	√	√	8
李芳^[15]	√	√	√	√	√	×	√	√	√	8
Liu^[16]	√	√	√	×	×	×	√	√	√	6
国钰梅^[17]	√	√	√	×	√	×	√	√	√	7
谷新医^[18]	√	√	√	×	√	√	√	√	√	8
刘宣^[19]	√	√	√	√	×	×	√	√	√	7
林绍鹏^[20]	√	√	√	×	×	×	√	√	√	6
韩玉乐^[21]	√	√	√	×	×	×	√	√	√	6
Zhang^[22]	√	√	√	×	×	×	√	√	√	6